207_Combined course Presentations
ACCORD 12/0405
CAO/ARO/ AIO-04
NSABP R-04
STAR-01
PETACC-6
Endpoint
PCR
16% both arms 4% vs 7%
14% vs 19%
12.8% vs 16.5% (p=0.038)
19% vs 21%
11.5% vs 13%
CRM
8% vs 13%
5% vs 6% No
2% vs 2%
data
Node + (stage III)
29% vs 26%
30% vs 26%
27% vs 26%
Not stated
27% vs 26%
Oxaliplatin Phase III trials: Control arm in red
Made with FlippingBook